Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Particularly, 28% (27/97) AD-associated sensors were involved in metabolic pathways (Fig. 2c), suggesting crucial roles of metabolites on mediating signaling pathways8. 12 sensors were specific to microglia, such as AD-associated peroxisome proliferator-activated receptor delta (PPARD) and vitamin D receptor (VDR) (Extended Data Figs. 2e,f).

Source: Discovery of neuron/microglia-specific metabolite-sensor networks in AD. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 1.38 million nuclei from post-mortem MTG brain region from 84 participants and 1.22 million nuclei from post-mortem DLPFC brain region from 80 participants were isolated.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Systematic characterization of cell type-specific master metabolic regulators in Alzheimer’s disease

Study design awaiting verification · Research Square · 2025

Original publication title

Systematic characterization of cell type-specific master metabolic regulators in Alzheimer’s disease

Yunguang Qiu; Yuan Hou; Liam Wetzel; Jessica Z.K. Caldwell; Xiongwei Zhu; Andrew A. Pieper; Tian Liu; Feixiong Cheng

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Alzheimer’s disease (AD) exhibits metabolic heterogeneity; yet, the consequences on metabolic dynamics in a cell-type-specific manner and the underlying metabolite-sensor network basis remain unclear. Here, we show that neurons exhibit a striking decrease in energy and lipid-related metabolic activity, contrasted by an increase in microglial metabolism associated with neuroinflammation. To identify brain cell-type specific master metabolic regulators underlying the metabolic alterations of AD, we introduce scFUMES (single cell FUnctional MEtabolite-Sensor), an algorithm integrating single-cell RNA sequencing, interactomics (protein-protein interactions), genomics, transcriptomics, and metabolomics from large human brain biobanks.

Applied to two AD-vulnerable regions (middle temporal gyrus and dorsolateral prefrontal cortex), scFUMES uncovers hundreds of AD-associated regulators, with neurons and microglia showing the most interactions. Particularly, scFUMES pinpoints genetics-informed master metabolic regulators across AD severity, sex and APOE genotype (e.g., PPARD-glycerol in microglia). Experimental testing reveals that two interaction pairs predicted by scFUMES, neuronal palmitic acid bound fatty acid binding protein 3 and gut metabolite indole-3-propionic acid binding to kynurenine aminotransferase 1, both lower pathological tau species in AD.

In summary, scFUMES identifies cell type-specific master metabolic regulators, offering insights into cellular metabolic heterogeneity and metabolism-targeted therapeutic strategies for AD and neurodegenerative diseases if broadly applied.

Authors’ abstract

Alzheimer’s disease (AD) exhibits metabolic heterogeneity; yet, the consequences on metabolic dynamics in a cell-type-specific manner and the underlying metabolite-sensor network basis remain unclear. Here, we show that neurons exhibit a striking decrease in energy and lipid-related metabolic activity, contrasted by an increase in microglial metabolism associated with neuroinflammation. To identify brain cell-type specific master metabolic regulators underlying the metabolic alterations of AD, we introduce scFUMES (single cell FUnctional MEtabolite-Sensor), an algorithm integrating single-cell RNA sequencing, interactomics (protein-protein interactions), genomics, transcriptomics, and metabolomics from large human brain biobanks.

Applied to two AD-vulnerable regions (middle temporal gyrus and dorsolateral prefrontal cortex), scFUMES uncovers hundreds of AD-associated regulators, with neurons and microglia showing the most interactions. Particularly, scFUMES pinpoints genetics-informed master metabolic regulators across AD severity, sex and APOE genotype (e.g., PPARD-glycerol in microglia). Experimental testing reveals that two interaction pairs predicted by scFUMES, neuronal palmitic acid bound fatty acid binding protein 3 and gut metabolite indole-3-propionic acid binding to kynurenine aminotransferase 1, both lower pathological tau species in AD.

In summary, scFUMES identifies cell type-specific master metabolic regulators, offering insights into cellular metabolic heterogeneity and metabolism-targeted therapeutic strategies for AD and neurodegenerative diseases if broadly applied.

Publication and source details

Original title: Systematic characterization of cell type-specific master metabolic regulators in Alzheimer’s disease

Yunguang Qiu; Yuan Hou; Liam Wetzel; Jessica Z.K. Caldwell; Xiongwei Zhu; Andrew A. Pieper; Tian Liu; Feixiong Cheng

Research Square · 2025

Author contributions

F.C., T.L., and Y.Q. conceived the study. Y. Q. performed computational analysis. L.W. performed in vitro experiments. Y.Q., Y.H. and L.W. performed all data analysis. X.Z., J.Z.K.C., A.A.P. discussed and interpreted the results. Y.Q. and T.L. wrote the draft manuscript. F.C., Y.Q., and T.L. revised the manuscript. All authors have read and approved the final manuscript.

* Corresponding authors: txl757@case.edu (T.L.)* Correspondence to: Feixiong Cheng, PhD, Cleveland Clinic Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA, Fax: 216-636-0009, chengf@ccf.org
https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.This work was primarily supported by the National Institute on Aging (NIA) under Award Number U01AG073323, R01AG066707, R01AG084250, R01AG076448, R01AG082118, R01AG092462, R01AG092591, RF1AG082211, and R21AG083003, and the National Institute of Neurological Disorders and Stroke (NINDS) under Award Number RF1NS133812, the Alzheimer’s Association award (ALZDISCOVERY-1051936), and the Alzheimer’s Disease Drug Discovery Foundation (ADDF) to F.C. AAP was supported by The Valour Foundation and Department of Veterans Affairs Merit Award I01BX005976. AAP is also supported as the Rebecca E. Barchas, MD, Professor in Translational Psychiatry of Case Western Reserve University and the Morley-Mather Chair in Neuropsychiatry of University Hospitals of Cleveland Medical Center. AAP also acknowledges support from NIH/NIA RO1AGs066707, NIH/NIA 1 U01 AG073323, the Louis Stokes VA Medical Center resources and facilities. This work was supported by grants from the National Institutes of Health (NIH) [R01AG086365 to T.L, R03AG084948 to T.L]. T.L was also supported by the Research Education component of the Cleveland Alzheimer’s Disease Research Center (NIA P30 AG072959).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T22:09:25.977285+00:00

DOI: 10.21203/rs.3.rs-7207381/v1 · PMC12393479